Rami E. S.
- Country
- Germany
- Department
- Klinik für Strahlentherapie und Radioonkologie
Research Overview
- Efficacy and Tolerability of Rectal Budesonide Suppositories for Acute Radiation Proctitis in Male Patients with Prostate Carcinoma: A Phase II Randomized Controlled Trial
- Phase 3 Evaluation of Pembrolizumab and Olaparib with Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer
- Phase III Randomized Study of Durvalumab with SBRT and Osimertinib in Unresected Stage I/II Lymph-Node Negative NSCLC with EGFR Mutation
Data & Insights
Has run more than one trial at 31 of 176 partner sites.
Specializations
Non-Small Cell Lung Cancer
The investigator specializes in treating early-stage and locally advanced non-small cell lung cancer (NSCLC), with particular focus on integrating radiation therapy with novel therapeutic approaches.
- Stage I/II NSCLC management
- Stereotactic body radiation therapy (SBRT)
- EGFR mutation-targeted therapy
Research interests include combining immunotherapy with radiation treatment modalities for improved patient outcomes.
Advanced Therapeutic Combinations
The investigator explores innovative treatment combinations incorporating immunotherapy and targeted therapies with conventional treatment approaches.
- Concurrent chemoradiation protocols
- PET-guided radiation therapy
- Accelerated treatment regimens
Expertise includes optimizing treatment sequences and combinations for enhanced therapeutic efficacy.
Head and Neck Cancer
The investigator focuses on treating squamous cell carcinoma of the head and neck, particularly in the post-surgical setting.
- Post-resection radiation therapy
- Novel therapeutic agents
- Treatment of cisplatin-ineligible patients
Research encompasses development of alternative treatment strategies for high-risk patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.